Teratogen Warnings and Educational Media

致畸警告和教育媒体

• 批准号: 6999248
• 负责人: Richard Charles Goldsworthy
• 金额: $ 37.64万
• 依托单位: ACADEMIC EDGE, INC.
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-01 至 2007-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6999248
• 关键词: Internet; clinical research; congenital disorders; disease /disorder prevention /control; drug adverse effect; educational resource design /development; female; health education; high risk behavior /lifestyle; human subject; information display; male; publications; symbolism; teratogens; women' s health

DESCRIPTION (provided by applicant): The prescription of pharmaceuticals with teratogenic properties has increased rapidly over the past decade, with the heightened use of Accutane, thalidomide and other birth-defect inducing drugs. The CDC found the warning symbol in use at the time of the study on some teratogenic pharmaceuticals to be confusing and subject to harmful misinterpretation. The warning label is often the first and central intervention. There is, therefore, an urgent need for symbols, warning labels, and educational media that convey the danger of taking teratogenic pharmaceuticals while pregnant or preconceptional. Following ANSI guidelines for symbol development and evaluation, the researchers canvassed existing symbols, generated root concepts, and internally developed preliminary candidate images and styles for a new symbol. As the project ensued, focus groups were conducted. The purpose of the focus groups shifted over time from generation of new symbol, text, and label ideas to evaluation of pre-developed symbols, text, and text symbol combinations. A final set of six pilot symbols were selected. The six pilot symbols were evaluated in a nationally distributed field trial that utilized a one-on-one interview methodology (n=300, 50 per image). The evaluation demonstrated significant progress toward a validated pharmaceutical label. Results have been accepted for publication. Phase II will further refine and validate the pharmaceutical symbol and label, create a series of similar symbols and warnings for use in other settings and with other hazards, and create a series of educational media modules to increase awareness of the symbols and warnings and to educate professionals and the public on teratogenicity. These materials will include a multimedia module, a reference web-site, a set of brochures for pharmacies and practitioners and small media materials for display. All materials will be delivered in both English and Spanish. Licensing and commercialization of the symbols and media will be sought through standards organizations, FDA, and corporate sponsors.

描述（由申请人提供）：在过去的十年中，致畸性药物的处方迅速增加，阿曲坦、沙利度胺和其他出生缺陷诱导药物的使用增加。美国疾病控制与预防中心发现，在对一些致畸药物进行研究时使用的警告标志令人困惑，容易产生有害的误解。警告标签通常是首要和主要的干预措施。因此，迫切需要符号、警告标签和教育媒体来传达怀孕或怀孕前服用致畸药物的危险。遵循ANSI符号开发和评估的指导方针，研究人员仔细检查了现有的符号，生成了根概念，并在内部为新符号开发了初步的候选图像和样式。随着项目的进行，进行了焦点小组讨论。随着时间的推移，焦点小组的目的从产生新的符号、文本和标签思想转变为评估预先开发的符号、文本和文本符号组合。最后选定了6个导频符号。六个试点符号在全国分布的现场试验中进行评估，该试验采用一对一访谈方法（每张图像n= 300,50）。该评估显示了在验证药品标签方面取得的重大进展。结果已被接受发表。第二阶段将进一步完善和验证药品符号和标签，创建一系列类似的符号和警告，用于其他环境和其他危害，并创建一系列教育媒体模块，以提高对符号和警告的认识，并对专业人员和公众进行致畸性教育。这些材料将包括一个多媒体模块、一个参考网站、一套供药店和从业人员使用的小册子以及用于展示的小型媒体材料。所有材料将以英语和西班牙语提供。将通过标准组织、FDA和企业赞助商寻求符号和媒体的许可和商业化。